The company confirmed it will host a webcast on Tuesday to unveil initial findings from the study. Beyond the raw data, management plans to outline an optimized design for the remaining stages of the phase 2 trial, a move intended to refine the drug's path toward potential regulatory approval. This steady growth follows a period of significant momentum for the firm, with current trading prices reaching $7.91.
Turn Therapeutics Rises as Dermatitis Trial Data Approaches
Investors pushed Turn Therapeutics shares up 2.9% in after-hours trading Monday, betting on the imminent release of phase 2 trial data for GX-03. The stock, which already climbed 8% during the regular session, has nearly doubled in value throughout the year as market anticipation for the dermatitis treatment intensifies.
Comments (0)
No comments yet. Be the first!